Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 28, 1998

View Archived Issues

Company Profile: Nymox

Major innovations fuel R&D at Astra

Agents for chronobiological disorders synthesized at Glaxo

PKC modulators for proliferative disorders described by Georgetown U.

New AIDS therapies in development in Korea

Indole endothelin antagonists prepared at Pfizer

Antitumor and antiviral distamycin derivatives from Pharmacia & Upjohn

Flavopiridol analogues as inhibitors of cyclin-dependent kinases

BMS discloses new Taxol derivative

Phenylglycine derivatives with mGluR-antagonist activity disclosed by Lilly

Positive U.S. phase II results for Thymoglobulin in preventing kidney transplant rejection

Anti-TNF strategy in MS treatment should be reconsidered

Rate-independent profile of antiarrhythmic agent suggests improved therapeutic potential

BioMarin's lead enzyme replacement therapy enters clinical trials

New test for cardiovascular disease risk assessment from Myriad Genetics

FDA panel recommends approval of Verdia

In vivo efficacy reported for angiotensin II blocker

EUK-134 effective in animal model of stroke

Allelix: Q1 1998 highlights

Antihypertensive efficacy described for Novartis' dual ACE/NEP inhibitor

Phase II trials of Sibia's Parkinson's disease Rx begin

Japanese approval for Biora's periodontal disease product

Pacific's cancer immunotherapy proves highly effective in rat metastatic mammary tumor model

Vaccine delivery joint venture finalized by Endorex and Elan

Viragen seeks to become fully integrated blood products company

ACT evaluated in second phase I trial in HIV/AIDS patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...